Home › Metastatic Cancer › Oklahoma
Metastatic Cancer clinical trials in Oklahoma
16 studies for Metastatic Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05803382Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06311214FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 19, 2026 · NCT05431270Collection and Storage of Tissue and Blood Samples From Patients With Cancer
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingObservational study
2 Months · All sexes · Updated Mar 5, 2026 · NCT02474160Circulating Tumor DNA Response In Urothelial Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT07183319SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Spine Radiosurgery for Symptomatic Metastatic Neoplasms
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2025 · NCT05617716A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.